Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma
CONCLUSION: Brexu-cel has emerged as a viable treatment option in MCL. Additional studies are required to determine the optimal sequencing and place in therapy for brexu-cel in this highly heterogeneous, pathobiologically distinct, and incurable malignancy.PMID:34340597 | DOI:10.1177/10600280211026338 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 3, 2021 Category: Drugs & Pharmacology Authors: Mary Kate Anderson Annie Torosyan Zachery Halford Source Type: research

Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Ann Pharmacother. 2021 Jul 30:10600280211036040. doi: 10.1177/10600280211036040. Online ahead of print.NO ABSTRACTPMID:34330160 | DOI:10.1177/10600280211036040 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Brittany D Bissell Breanne Mefford J Chris Donaldson Source Type: research

Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies
CONCLUSION: The development of novel and investigational therapeutic agents continues to contribute to an improved understanding of tumor biology. The precise therapeutic role and timing of these agents remain to be elucidated.PMID:34330162 | DOI:10.1177/10600280211036154 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Clement Chung Source Type: research

Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Ann Pharmacother. 2021 Jul 30:10600280211036047. doi: 10.1177/10600280211036047. Online ahead of print.NO ABSTRACTPMID:34330173 | DOI:10.1177/10600280211036047 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Xian Jie Cindy Chen Diana Altshuler Peter Spiegler Shari B Brosnahan Source Type: research

Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Ann Pharmacother. 2021 Jul 30:10600280211036040. doi: 10.1177/10600280211036040. Online ahead of print.NO ABSTRACTPMID:34330160 | DOI:10.1177/10600280211036040 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Brittany D Bissell Breanne Mefford J Chris Donaldson Source Type: research

Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies
CONCLUSION: The development of novel and investigational therapeutic agents continues to contribute to an improved understanding of tumor biology. The precise therapeutic role and timing of these agents remain to be elucidated.PMID:34330162 | DOI:10.1177/10600280211036154 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Clement Chung Source Type: research

Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Ann Pharmacother. 2021 Jul 30:10600280211036047. doi: 10.1177/10600280211036047. Online ahead of print.NO ABSTRACTPMID:34330173 | DOI:10.1177/10600280211036047 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Xian Jie Cindy Chen Diana Altshuler Peter Spiegler Shari B Brosnahan Source Type: research

Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Ann Pharmacother. 2021 Jul 30:10600280211036040. doi: 10.1177/10600280211036040. Online ahead of print.NO ABSTRACTPMID:34330160 | DOI:10.1177/10600280211036040 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Brittany D Bissell Breanne Mefford J Chris Donaldson Source Type: research

Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies
CONCLUSION: The development of novel and investigational therapeutic agents continues to contribute to an improved understanding of tumor biology. The precise therapeutic role and timing of these agents remain to be elucidated.PMID:34330162 | DOI:10.1177/10600280211036154 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Clement Chung Source Type: research

Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk
Ann Pharmacother. 2021 Jul 30:10600280211036047. doi: 10.1177/10600280211036047. Online ahead of print.NO ABSTRACTPMID:34330173 | DOI:10.1177/10600280211036047 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 31, 2021 Category: Drugs & Pharmacology Authors: Xian Jie Cindy Chen Diana Altshuler Peter Spiegler Shari B Brosnahan Source Type: research

Novel Use of Fostemsavir for 2 Multidrug-Resistant Persons With Human Immunodeficiency Virus
Ann Pharmacother. 2021 Jul 30:10600280211035510. doi: 10.1177/10600280211035510. Online ahead of print.NO ABSTRACTPMID:34328023 | DOI:10.1177/10600280211035510 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 30, 2021 Category: Drugs & Pharmacology Authors: Patricia Pecora Fulco Daniel Nixon Denese C Gomes Source Type: research

Novel Use of Fostemsavir for 2 Multidrug-Resistant Persons With Human Immunodeficiency Virus
Ann Pharmacother. 2021 Jul 30:10600280211035510. doi: 10.1177/10600280211035510. Online ahead of print.NO ABSTRACTPMID:34328023 | DOI:10.1177/10600280211035510 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 30, 2021 Category: Drugs & Pharmacology Authors: Patricia Pecora Fulco Daniel Nixon Denese C Gomes Source Type: research

Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2-Associated Acute Respiratory Failure
CONCLUSION AND RELEVANCE: In the first published report of its use within this population, bivalirudin was found to be a viable choice for anticoagulation in those patients on ECMO for severe respiratory failure secondary to COVID-19.PMID:34323121 | DOI:10.1177/10600280211036151 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 29, 2021 Category: Drugs & Pharmacology Authors: Brittany D Bissell Taylor Gabbard Erica A Sheridan Maher A Baz George A Davis Ayesha Ather Source Type: research

Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2-Associated Acute Respiratory Failure
CONCLUSION AND RELEVANCE: In the first published report of its use within this population, bivalirudin was found to be a viable choice for anticoagulation in those patients on ECMO for severe respiratory failure secondary to COVID-19.PMID:34323121 | DOI:10.1177/10600280211036151 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 29, 2021 Category: Drugs & Pharmacology Authors: Brittany D Bissell Taylor Gabbard Erica A Sheridan Maher A Baz George A Davis Ayesha Ather Source Type: research

Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care
CONCLUSIONS: Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.PMID:34301151 | DOI:10.1177/10600280211033022 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Lisa Burry Justin Turner Timothy Morgenthaler Cara Tannenbaum Hyung J Cho Evelyn Gathecha Flora Kisuule Abi Vijenthira Christine Soong Source Type: research

1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
Ann Pharmacother. 2021 Jul 23:10600280211031329. doi: 10.1177/10600280211031329. Online ahead of print.ABSTRACTOBJECTIVE: Actinic keratoses (AKs) are cutaneous lesions that arise in sun-damaged skin. AKs may transform into squamous cell carcinoma in situ. Tirbanibulin 1% ointment is a new topical treatment for AKs, recently approved by the Food and Drug Administration.DATA SOURCES: The PubMed database was searched for articles published from 1960 to March 31, 2021, using the keywords tirbanibulin and Klisyri.DATA EXTRACTION: Phase 2 and phase 3 clinical trials were reviewed.DATA SYNTHESIS: In phase 2 clinical trials, 43% o...
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Diem-Phuong D Dao Vikram Nath Sahni Dev Ram Sahni Esther A Balogh Ayman Grada Steven R Feldman Source Type: research

Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care
CONCLUSIONS: Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.PMID:34301151 | DOI:10.1177/10600280211033022 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Lisa Burry Justin Turner Timothy Morgenthaler Cara Tannenbaum Hyung J Cho Evelyn Gathecha Flora Kisuule Abi Vijenthira Christine Soong Source Type: research

1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
Ann Pharmacother. 2021 Jul 23:10600280211031329. doi: 10.1177/10600280211031329. Online ahead of print.ABSTRACTOBJECTIVE: Actinic keratoses (AKs) are cutaneous lesions that arise in sun-damaged skin. AKs may transform into squamous cell carcinoma in situ. Tirbanibulin 1% ointment is a new topical treatment for AKs, recently approved by the Food and Drug Administration.DATA SOURCES: The PubMed database was searched for articles published from 1960 to March 31, 2021, using the keywords tirbanibulin and Klisyri.DATA EXTRACTION: Phase 2 and phase 3 clinical trials were reviewed.DATA SYNTHESIS: In phase 2 clinical trials, 43% o...
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Diem-Phuong D Dao Vikram Nath Sahni Dev Ram Sahni Esther A Balogh Ayman Grada Steven R Feldman Source Type: research

Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care
CONCLUSIONS: Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.PMID:34301151 | DOI:10.1177/10600280211033022 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Lisa Burry Justin Turner Timothy Morgenthaler Cara Tannenbaum Hyung J Cho Evelyn Gathecha Flora Kisuule Abi Vijenthira Christine Soong Source Type: research

1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
Ann Pharmacother. 2021 Jul 23:10600280211031329. doi: 10.1177/10600280211031329. Online ahead of print.ABSTRACTOBJECTIVE: Actinic keratoses (AKs) are cutaneous lesions that arise in sun-damaged skin. AKs may transform into squamous cell carcinoma in situ. Tirbanibulin 1% ointment is a new topical treatment for AKs, recently approved by the Food and Drug Administration.DATA SOURCES: The PubMed database was searched for articles published from 1960 to March 31, 2021, using the keywords tirbanibulin and Klisyri.DATA EXTRACTION: Phase 2 and phase 3 clinical trials were reviewed.DATA SYNTHESIS: In phase 2 clinical trials, 43% o...
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Diem-Phuong D Dao Vikram Nath Sahni Dev Ram Sahni Esther A Balogh Ayman Grada Steven R Feldman Source Type: research

Addressing Barriers to Reducing Prescribing and Implementing Deprescribing of Sedative-Hypnotics in Primary Care
CONCLUSIONS: Several strategies with demonstrated efficacy in reducing SH use in community practice were identified. Education regarding SH risks, how to taper, and potential alternatives are essential details to provide to clinicians, patients, and families. The strategies presented can guide community healthcare teams toward reducing the community burden of SH use.PMID:34301151 | DOI:10.1177/10600280211033022 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Lisa Burry Justin Turner Timothy Morgenthaler Cara Tannenbaum Hyung J Cho Evelyn Gathecha Flora Kisuule Abi Vijenthira Christine Soong Source Type: research

1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
Ann Pharmacother. 2021 Jul 23:10600280211031329. doi: 10.1177/10600280211031329. Online ahead of print.ABSTRACTOBJECTIVE: Actinic keratoses (AKs) are cutaneous lesions that arise in sun-damaged skin. AKs may transform into squamous cell carcinoma in situ. Tirbanibulin 1% ointment is a new topical treatment for AKs, recently approved by the Food and Drug Administration.DATA SOURCES: The PubMed database was searched for articles published from 1960 to March 31, 2021, using the keywords tirbanibulin and Klisyri.DATA EXTRACTION: Phase 2 and phase 3 clinical trials were reviewed.DATA SYNTHESIS: In phase 2 clinical trials, 43% o...
Source: The Annals of Pharmacotherapy - July 24, 2021 Category: Drugs & Pharmacology Authors: Diem-Phuong D Dao Vikram Nath Sahni Dev Ram Sahni Esther A Balogh Ayman Grada Steven R Feldman Source Type: research

Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults
Ann Pharmacother. 2021 Jul 22:10600280211034176. doi: 10.1177/10600280211034176. Online ahead of print.ABSTRACTBACKGROUND: Dolutegravir (DTG) plus lamivudine (2-DR) is suggested as an initial and switch option in HIV-1 treatment.OBJECTIVE: To analyze the effectiveness, durability, and safety of 2-DR compared with DTG plus abacavir/lamivudine (3-DR).METHODS: This was an observational, ambispective study that included all treatment-naïve (TN) and treatment-experienced (TE) patients who started 2-DR or 3-DR between July 1, 2018, and November 30, 2020. The primary end point was noninferiority, at 24 and 48 weeks, of 2-DR ...
Source: The Annals of Pharmacotherapy - July 23, 2021 Category: Drugs & Pharmacology Authors: In és Mendoza Alicia L ázaro Miguel Torralba Source Type: research

Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults
Ann Pharmacother. 2021 Jul 22:10600280211034176. doi: 10.1177/10600280211034176. Online ahead of print.ABSTRACTBACKGROUND: Dolutegravir (DTG) plus lamivudine (2-DR) is suggested as an initial and switch option in HIV-1 treatment.OBJECTIVE: To analyze the effectiveness, durability, and safety of 2-DR compared with DTG plus abacavir/lamivudine (3-DR).METHODS: This was an observational, ambispective study that included all treatment-naïve (TN) and treatment-experienced (TE) patients who started 2-DR or 3-DR between July 1, 2018, and November 30, 2020. The primary end point was noninferiority, at 24 and 48 weeks, of 2-DR ...
Source: The Annals of Pharmacotherapy - July 23, 2021 Category: Drugs & Pharmacology Authors: In és Mendoza Alicia L ázaro Miguel Torralba Source Type: research

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
CONCLUSION AND RELEVANCE: Concomitant PPI use was not associated with the effectiveness of nivolumab or pembrolizumab. Certain predictors of survival outcomes related to PPI use in patients receiving immunotherapy, such as the time window and indication of PPI exposure and autoimmune disorders, should be explored in the future to better carve out the impact of PPI on the effectiveness of ICI use.PMID:34282636 | DOI:10.1177/10600280211033938 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Kangning Peng Ken Chen Benjamin A Teply Gary C Yee Paraskevi A Farazi Elizabeth R Lyden Source Type: research

Underreported Risk of Lisinopril-Induced Angioedema in a Veteran Population
CONCLUSION AND RELEVANCE: When estimating the effect of underreporting, the risk of LIA increases to approximately 1.6% or 1 in 63 patients. Because this ADE may affect more patients than previously understood, providers may wish to take LIA into consideration when prescribing lisinopril.PMID:34282637 | DOI:10.1177/10600280211032404 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Whitley J Whitehead Jennifer Meyer Reid Source Type: research

Association Between Potentially Inappropriate Medications and 30-Day Post-Hospital Discharge Outcomes in US Veterans
CONCLUSION AND RELEVANCE: PIMs were highly common in this veteran cohort, and the association with outcomes differed by PIMs. Thus, it is important to consider whether PIMs are CNS acting to optimize short-term posthospitalization outcomes.PMID:34282638 | DOI:10.1177/10600280211032072 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Heather G Allore Danijela Gnjidic Melissa Skanderson Ling Han Source Type: research

Treatment of Acute Gout Flares in the Emergency Department: Prescribing Patterns and Revisit Rates
CONCLUSION AND RELEVANCE: Roughly 30% of patients did not receive an anti-inflammatory on discharge, and opioids were frequently overused in gout management in the ED. There is an opportunity for further education of health care providers regarding gout treatment.PMID:34282640 | DOI:10.1177/10600280211032295 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Luigi Brunetti Janaki Vekaria Peter E Lipsky Naomi Schlesinger Source Type: research

Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema
Ann Pharmacother. 2021 Jul 20:10600280211032982. doi: 10.1177/10600280211032982. Online ahead of print.ABSTRACTOBJECTIVE: The purpose of this article is to review the available trials that led to the Food and Drug Administration (FDA) approval of berotralstat, an oral kallikrein inhibitor, for the prevention of hereditary angioedema (HAE) attacks.DATA SOURCES: PubMed and ClincalTrials.gov were searched using key term berotralstat to identify phase III clinical trials related to the FDA approval of berotralstat from April 2018 to May 2021.STUDY SELECTION AND DATA EXTRACTION: Trials selected were those that influenced the FD...
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Jason Powell Chris Piszczatoski Eric Rubido Source Type: research

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
CONCLUSION AND RELEVANCE: Concomitant PPI use was not associated with the effectiveness of nivolumab or pembrolizumab. Certain predictors of survival outcomes related to PPI use in patients receiving immunotherapy, such as the time window and indication of PPI exposure and autoimmune disorders, should be explored in the future to better carve out the impact of PPI on the effectiveness of ICI use.PMID:34282636 | DOI:10.1177/10600280211033938 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Kangning Peng Ken Chen Benjamin A Teply Gary C Yee Paraskevi A Farazi Elizabeth R Lyden Source Type: research

Underreported Risk of Lisinopril-Induced Angioedema in a Veteran Population
CONCLUSION AND RELEVANCE: When estimating the effect of underreporting, the risk of LIA increases to approximately 1.6% or 1 in 63 patients. Because this ADE may affect more patients than previously understood, providers may wish to take LIA into consideration when prescribing lisinopril.PMID:34282637 | DOI:10.1177/10600280211032404 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Whitley J Whitehead Jennifer Meyer Reid Source Type: research

Association Between Potentially Inappropriate Medications and 30-Day Post-Hospital Discharge Outcomes in US Veterans
CONCLUSION AND RELEVANCE: PIMs were highly common in this veteran cohort, and the association with outcomes differed by PIMs. Thus, it is important to consider whether PIMs are CNS acting to optimize short-term posthospitalization outcomes.PMID:34282638 | DOI:10.1177/10600280211032072 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Heather G Allore Danijela Gnjidic Melissa Skanderson Ling Han Source Type: research

Treatment of Acute Gout Flares in the Emergency Department: Prescribing Patterns and Revisit Rates
CONCLUSION AND RELEVANCE: Roughly 30% of patients did not receive an anti-inflammatory on discharge, and opioids were frequently overused in gout management in the ED. There is an opportunity for further education of health care providers regarding gout treatment.PMID:34282640 | DOI:10.1177/10600280211032295 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Luigi Brunetti Janaki Vekaria Peter E Lipsky Naomi Schlesinger Source Type: research

Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema
Ann Pharmacother. 2021 Jul 20:10600280211032982. doi: 10.1177/10600280211032982. Online ahead of print.ABSTRACTOBJECTIVE: The purpose of this article is to review the available trials that led to the Food and Drug Administration (FDA) approval of berotralstat, an oral kallikrein inhibitor, for the prevention of hereditary angioedema (HAE) attacks.DATA SOURCES: PubMed and ClincalTrials.gov were searched using key term berotralstat to identify phase III clinical trials related to the FDA approval of berotralstat from April 2018 to May 2021.STUDY SELECTION AND DATA EXTRACTION: Trials selected were those that influenced the FD...
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Jason Powell Chris Piszczatoski Eric Rubido Source Type: research

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
CONCLUSION AND RELEVANCE: Concomitant PPI use was not associated with the effectiveness of nivolumab or pembrolizumab. Certain predictors of survival outcomes related to PPI use in patients receiving immunotherapy, such as the time window and indication of PPI exposure and autoimmune disorders, should be explored in the future to better carve out the impact of PPI on the effectiveness of ICI use.PMID:34282636 | DOI:10.1177/10600280211033938 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Kangning Peng Ken Chen Benjamin A Teply Gary C Yee Paraskevi A Farazi Elizabeth R Lyden Source Type: research

Underreported Risk of Lisinopril-Induced Angioedema in a Veteran Population
CONCLUSION AND RELEVANCE: When estimating the effect of underreporting, the risk of LIA increases to approximately 1.6% or 1 in 63 patients. Because this ADE may affect more patients than previously understood, providers may wish to take LIA into consideration when prescribing lisinopril.PMID:34282637 | DOI:10.1177/10600280211032404 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Whitley J Whitehead Jennifer Meyer Reid Source Type: research

Association Between Potentially Inappropriate Medications and 30-Day Post-Hospital Discharge Outcomes in US Veterans
CONCLUSION AND RELEVANCE: PIMs were highly common in this veteran cohort, and the association with outcomes differed by PIMs. Thus, it is important to consider whether PIMs are CNS acting to optimize short-term posthospitalization outcomes.PMID:34282638 | DOI:10.1177/10600280211032072 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Heather G Allore Danijela Gnjidic Melissa Skanderson Ling Han Source Type: research

Treatment of Acute Gout Flares in the Emergency Department: Prescribing Patterns and Revisit Rates
CONCLUSION AND RELEVANCE: Roughly 30% of patients did not receive an anti-inflammatory on discharge, and opioids were frequently overused in gout management in the ED. There is an opportunity for further education of health care providers regarding gout treatment.PMID:34282640 | DOI:10.1177/10600280211032295 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Luigi Brunetti Janaki Vekaria Peter E Lipsky Naomi Schlesinger Source Type: research

Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema
Ann Pharmacother. 2021 Jul 20:10600280211032982. doi: 10.1177/10600280211032982. Online ahead of print.ABSTRACTOBJECTIVE: The purpose of this article is to review the available trials that led to the Food and Drug Administration (FDA) approval of berotralstat, an oral kallikrein inhibitor, for the prevention of hereditary angioedema (HAE) attacks.DATA SOURCES: PubMed and ClincalTrials.gov were searched using key term berotralstat to identify phase III clinical trials related to the FDA approval of berotralstat from April 2018 to May 2021.STUDY SELECTION AND DATA EXTRACTION: Trials selected were those that influenced the FD...
Source: The Annals of Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Jason Powell Chris Piszczatoski Eric Rubido Source Type: research

Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver
Ann Pharmacother. 2021 Jul 14:10600280211032293. doi: 10.1177/10600280211032293. Online ahead of print.NO ABSTRACTPMID:34259073 | DOI:10.1177/10600280211032293 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Zachary S Robinson Katharine L Madding Dylan Magoto Source Type: research

Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
CONCLUSIONS: The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.PMID:34259076 | DOI:10.1177/10600280211031390 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Elias B Chahine John A Dougherty Krisy-Ann Thornby Erenie H Guirguis Source Type: research

Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver
Ann Pharmacother. 2021 Jul 14:10600280211032293. doi: 10.1177/10600280211032293. Online ahead of print.NO ABSTRACTPMID:34259073 | DOI:10.1177/10600280211032293 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Zachary S Robinson Katharine L Madding Dylan Magoto Source Type: research

Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
CONCLUSIONS: The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.PMID:34259076 | DOI:10.1177/10600280211031390 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Elias B Chahine John A Dougherty Krisy-Ann Thornby Erenie H Guirguis Source Type: research

Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver
Ann Pharmacother. 2021 Jul 14:10600280211032293. doi: 10.1177/10600280211032293. Online ahead of print.NO ABSTRACTPMID:34259073 | DOI:10.1177/10600280211032293 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Zachary S Robinson Katharine L Madding Dylan Magoto Source Type: research

Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
CONCLUSIONS: The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.PMID:34259076 | DOI:10.1177/10600280211031390 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Elias B Chahine John A Dougherty Krisy-Ann Thornby Erenie H Guirguis Source Type: research

Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver
Ann Pharmacother. 2021 Jul 14:10600280211032293. doi: 10.1177/10600280211032293. Online ahead of print.NO ABSTRACTPMID:34259073 | DOI:10.1177/10600280211032293 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Zachary S Robinson Katharine L Madding Dylan Magoto Source Type: research

Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
CONCLUSIONS: The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.PMID:34259076 | DOI:10.1177/10600280211031390 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Elias B Chahine John A Dougherty Krisy-Ann Thornby Erenie H Guirguis Source Type: research

Delayed Rivaroxaban Elimination in Acute Kidney Injury and Shock Liver
Ann Pharmacother. 2021 Jul 14:10600280211032293. doi: 10.1177/10600280211032293. Online ahead of print.NO ABSTRACTPMID:34259073 | DOI:10.1177/10600280211032293 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Zachary S Robinson Katharine L Madding Dylan Magoto Source Type: research

Antibiotic Approvals in the Last Decade: Are We Keeping Up With Resistance?
CONCLUSIONS: The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.PMID:34259076 | DOI:10.1177/10600280211031390 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - July 14, 2021 Category: Drugs & Pharmacology Authors: Elias B Chahine John A Dougherty Krisy-Ann Thornby Erenie H Guirguis Source Type: research

Safety, Efficacy, and Cost of 0.4-mg Versus 2-mg Intranasal Naloxone for Treatment of Prehospital Opioid Overdose
Ann Pharmacother. 2021 Jul 6:10600280211030918. doi: 10.1177/10600280211030918. Online ahead of print.ABSTRACTBACKGROUND: Intranasal naloxone is commonly used to treat prehospital opioid overdose. However, the optimal dose is unclear, and currently, no study exists comparing the clinical effect of intranasal naloxone at different doses.OBJECTIVE: The goal of this investigation was to compare the safety, efficacy, and cost of 0.4- versus 2-mg intranasal naloxone for treatment of prehospital opioid overdose.METHODS: A retrospective, cross-sectional study was performed of 218 consecutive adult patients receiving intranasal na...
Source: The Annals of Pharmacotherapy - July 7, 2021 Category: Drugs & Pharmacology Authors: John Thompson Jenna Salter Peter Bui Logan Herbert David Mills Deborah Wagner Christine Brent Source Type: research